VEGFA and idiopathic pulmonary fibrosis: Nintedanib, which suppresses the production of fibrosis-related factor receptors such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF), is approved as a treatment medication for patients with idiopathic pulmonary fibrosis.